Last Updated : May 9, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Otezla | Apremilast | Arthritis, psoriatic | List with criteria/condition | Complete | ||
| Cimzia | Certolizumab pegol | Arthritis, psoriatic | List with criteria/condition | Complete | ||
| Stelara | Ustekinumab | Arthritis, psoriatic | Do not list at the submitted price | Complete | ||
| Simponi | Golimumab | Arthritis, psoriatic | List in a similar manner | Complete | ||
| Humira | Adalimumab | Arthritis, Psoriatic | List with clinical criteria and/or conditions | Complete | ||
| Cosentyx | Secukinumab | Arthritis, psoriatic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Olumiant | baricitinib | Arthritis, Rheumatoid | Reimburse with clinical criteria and/or conditions | Complete | ||
| Rinvoq | upadacitinib | Arthritis, Rheumatoid | Reimburse with clinical criteria and/or conditions | Complete | ||
| TBC | filgotinib | Arthritis, Rheumatoid | Withdrawn | |||
| Kevzara | sarilumab | Arthritis, Rheumatoid | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 9, 2024